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Blinatumomab in pediatric patients with relapsed/
refractory acute lymphoblastic leukemia: results of
the RIALTO trial, an expanded access study
Franco Locatelli1, Gerhard Zugmaier 2, Noemi Mergen2, Peter Bader3, Sima Jeha4, Paul-Gerhardt Schlegel5,
Jean-Pierre Bourquin6, Rupert Handgretinger7, Benoit Brethon8, Claudia Rossig9 and Christiane Chen-Santel10
Dear Editor,
Although most children with B-cell precursor acute
lymphoblastic leukemia (BCP-ALL) achieve first remis-
sion with conventional, risk-adapted protocols, relapse
still occurs in 15–20% of patients1. Current salvage
treatments are associated with acute and long-term toxi-
cities, which may cause long-term sequelae and
treatment-related (TR) death2. As minimal residual dis-
ease (MRD) is a strong predictor of relapse in BCP-ALL3,
new treatments associated with reduced toxicity and high
rates of MRD clearance are needed to improve outcomes
for children with relapsed/refractory (r/r) BCP-ALL.
Blinatumomab is a bispecific CD19-directed CD3 T-cell
engager (BiTE) molecule shown to improve overall sur-
vival (OS) as compared with standard chemotherapy in
adult patients with r/r BCP-ALL, and to induce high rates
of complete remission (CR) and complete MRD
response4–6. An international phase 1/2 study established
the recommended dose of blinatumomab in children and
adolescents with r/r BCP-ALL, and demonstrated its
antileukemic activity across age and risk groups7.
We report on the safety and efficacy of blinatumomab in
an open-label, single-arm, expanded access international
study of pediatric patients with CD19-positive r/r BCP-
ALL (RIALTO trial, NCT02187354). The protocol was
approved by the Institutional Review Board/Independent
Ethics Committee at each site; informed consent was
obtained from patients’ legal guardians. Enrolled patients
were aged >28 days to <18 years, with CD19-positive
BCP-ALL in second or later relapse, any relapse after
allogeneic hematopoietic stem cell transplantation
(alloHSCT), or refractory to other treatments. All patients
had ≥5% blasts or <5% blasts but with MRD level ≥ 10−3,
and adequate liver function at screening. Blinatumomab
(5–15 µg/m2 per day) was administered as a 6-week
induction cycle, comprising continuous infusion for
4 weeks, followed by a 2-week treatment-free period. Up
to two induction cycles could be performed. Those
achieving CR could then receive up to three additional
consolidation cycles for a total of five cycles. Additional
eligibility criteria, dosing information, and dose inter-
ruption or discontinuation criteria are included in Sup-
plementary Material.
The primary endpoint was incidence of treatment-
emergent (TE) and TR adverse events (AEs). Secondary
endpoints included morphologic CR (<5% blasts) and
MRD response (<10−4 leukemic blasts by flow cytometry)
in the first two cycles, relapse-free survival (RFS), OS,
alloHSCT rate after blinatumomab treatment, and 100-
day mortality after alloHSCT. Bone marrow aspirate or
biopsy was performed at screening, after blinatumomab
infusion on day 29 of each treatment cycle, and 6-monthly
during follow-up, until 18 months after the first blinatu-
momab dose. Statistical analyses are described in Sup-
plementary Material.
The study began in 2014. Data cut-off for the current
analysis was July 19, 2019. Baseline demographics and
clinical characteristics for all patients (n= 110; full ana-
lysis set) are shown in Supplementary Table 1. Eleven
percent (n= 12) had <5% blasts (with MRD ≥ 10−3) at
baseline. Thirty-two patients remained on treatment at
the cut-off date (Supplementary Fig. 1).
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Almost all patients (99%) experienced TEAEs (Supple-
mentary Table 2); AEs of ≥grade 3 were experienced by
65% of patients. TRAEs were reported in 74% of patients;
26% were ≥grade 3 (Supplementary Table 2). TRAEs
leading to blinatumomab discontinuation or temporary
interruption occurred in 4% and 16% of patients,
respectively. There were nine fatal AEs; none were
attributed to blinatumomab. Forty-two percent of patients
experienced neurologic AEs, most commonly headache
(25%). Six patients (5.5%) experienced grade 3 neurologic
events: two patients experienced headache, and one
patient each had depressed level of consciousness, seizure,
trigeminal nerve disorder, and agitation. AEs were man-
aged per protocol (see “Treatments” in Supplementary
Material). There were no grade 4 or 5 neurologic AEs.
Two patients (1.8%) experienced grade ≥ 3 cytokine
release syndrome (CRS), and one (1%) had grade 4 CRS.
Among patients with ≥5% blasts at baseline (n= 98), 58
patients (59%) achieved CR within the first two blinatu-
momab cycles. Of these, 39 (67%) also achieved full
hematologic recovery and 46 (79%) achieved MRD
response (Supplementary Table 3). Details of patients
with nonevaluable or unavailable response data are given
in the Supplementary Material. Of the twelve patients
enrolled with <5% blasts, 11 (92%) achieved MRD
response during the first two blinatumomab cycles
including three with full recovery of peripheral blood
counts, while response data were unavailable for one
patient.
Overall, the response rate was higher among patients with
lower baseline tumor burden (Fig. 1). Four of five patients
with prior blinatumomab exposure achieved CR with full
recovery of peripheral blood counts, and three achieved
MRD response in the first two cycles. Two patients had t
(17;19) rearrangement and both achieved CR with MRD
response in the first two treatment cycles; both completed
the study in remission and were alive at last follow-up.
Three of the four patients with constitutional trisomy 21
achieved CR with MRD response, two completed the study
in remission and were still alive at last follow-up.
Of 110 patients in the study, 69 patients had CR as best
response in the first two cycles; of these, 45 (65%) pro-
ceeded to alloHSCT. Simon–Makuch 42-day landmark
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Fig. 1 Response rates within the first 2 cycles of blinatumomab treatment, by subgroup. a Complete remission (CR) rates in patients with ≥5%
blasts at baseline. b Minimal residual disease (MRD) response rates.
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patients who received alloHSCT after blinatumomab
as compared with those who did not (Fig. 2e, f).
The Kaplan–Meier estimate of 100-day mortality
following alloHSCT for these patients (n= 45) was 4.5%
(95% CI 1.2–17.0%). Six of twenty-three relapses (26%)
were CD19-negative.
Median OS for all patients (n= 110) was 13.1 months
(95% CI 10.2–21.3), with a median follow-up of
17.4 months (Fig. 2a). For all patients reaching or main-
taining CR in the first two cycles of blinatumomab (n=
69), median RFS was 8.5 months (95% CI 4.4—not eva-
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Fig. 2 Kaplan–Meier and Simon–Makuch analyses of overall survival (OS) and relapse-free survival (RFS). For the Kaplan–Meier analyses, OS
was analyzed in the full analysis set, overall (a) and according to the minimal residual disease (MRD) response (c), and RFS was analyzed in all patients
who achieved complete remission (CR), overall (b) and according to the MRD response (d), calculated from time of CR. For the Simon–Makuch
analyses, both OS (e) and RFS (f) were analyzed according to the alloHSCT status post blinatumomab. RFS is calculated only on patients with CR.
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23 patients (33%) relapsed and 6 (9%) died. Those who
achieved MRD response had longer OS than those who
achieved CR without MRD response; however, there was
no apparent difference in RFS between these subgroups
(Fig. 2c, d). For patients given HSCT in continuous CR,
OS was nonestimable at the 15-month analysis for both
the MRD responders and nonresponders groups (Sup-
plementary Fig. 2).
Our findings demonstrate an acceptable safety profile
and high response rate with blinatumomab in pediatric
patients with r/r BCP-ALL. Blinatumomab is generally
better tolerated compared with chemotherapy5,8,9; how-
ever, it is associated with distinct AEs, including neuro-
logic toxicities and CRS. In this study, such events at
≥grade 3 were infrequent. Incidence of grade 3/4 AEs was
lower than in the recent phase 2 pediatric study7, possibly
reflecting the lower tumor burden of patients recruited
here. Overall, the safety profile was consistent with that
reported in other studies of blinatumomab4,6,7.
Our efficacy findings showed a trend similar to that
observed in the recent phase 2 study of blinatumomab in
pediatric patients with r/r BCP-ALL, in which a higher CR
rate was seen in patients with lower baseline blast counts7.
This explains the increased response rate observed here
compared with the phase 2 trial, since a higher proportion
of patients with <50% blasts were enrolled (61% of
patients versus 26% in the phase 2 study)7.
Blinatumomab demonstrated a 78% molecular response
rate in adult patients in morphological remission (<5%
blasts with MRD levels ≥10−3);4 ours is the first pediatric
study to include patients with these disease character-
istics. Of the 12 patients recruited, 11 achieved MRD
response within the first two blinatumomab cycles, sug-
gesting that further investigation in this patient popula-
tion is warranted.
There was no apparent difference in response rates
according to the number of prior relapses or prior
alloHSCT. This contrasts with chemotherapy out-
comes, where response rates decline with each con-
secutive relapse10. Only five patients had received prior
blinatumomab, but four of five achieved CR, and three
achieved MRD response, indicating that reexposure to
blinatumomab may be effective, provided that leukemia
blasts are still CD19-positive; CD19-negative relapse, a
tumor-escape mechanism, indicates a poor prognosis11.
Achievement of CR in three of four patients with con-
stitutional trisomy 21 suggests that blinatumomab
could be particularly useful to treat these fragile
patients at risk of experiencing severe toxicities when
exposed to aggressive chemotherapy12. Remarkably,
both patients with t(17;19) rearrangement obtained CR
with MRD response, this finding corroborating recent
data on blinatumomab efficacy in this peculiar patient
subset13.
A recent meta-analysis reported a significant OS benefit
for pediatric patients who achieved MRD negativity rela-
tive to those who did not3. Here, Kaplan–Meier analyses
show improved OS for patients who achieved MRD
response as compared with those who did not, with no
difference in RFS, possibly because of the low number of
patients in the MRD nonresponder group (n= 12).
Among patients with CR as best response in the first two
blinatumomab cycles, 65% proceeded to alloHSCT, and
these patients appeared to have longer RFS and OS
compared with patients who did not subsequently receive
alloHSCT, a finding consistent with the phase 2 pediatric
trial7. Our study is limited by the lack of a comparator
arm and the assessment of outcomes by investigators
rather than by independent central review.
Targeted immunotherapies other than blinatumomab
are being developed and have demonstrated activity in
pediatric patients with r/r BCP-ALL. These include ino-
tuzumab ozogamicin, although not approved for pediatric
patients14, and CD19-directed chimeric antigen receptor
T-cell therapies15–17. These trials highlight expansion of
treatment options beyond standard of care chemother-
apeutic approaches in patients with r/r BCP-ALL.
This expanded access study with blinatumomab in
pediatric patients with r/r BCP-ALL confirms a tolerable
safety profile and indicates a response rate higher than
previously reported, further supporting the use of blina-
tumomab for treatment of children with BCP-ALL.
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